A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

Serena Williams is opening up about her fitness journey, revealing that she uses the injectable GLP-1 weight loss drug ...

Given the potential side effects of GLP-1 prescription drugs, many Utahns are seeking alternative methods to naturally boost ...

Tennis champion Serena Williams has caused a stir after revealing that using GLP-1 medication has been key to her weight-loss ...

Glucagon-like-peptide-1 agonists like Ozempic have become extremely popular for weight loss. In fact, about 1 in 8 Americans have taken a GLP-1 drug at some point in their life, according to KFF ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

According to published results, glucagon-like peptide-1 agonists may not be associated with increased complications for patients with diabetes who undergo total hip arthroplasty.Results showed ...

DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results ...

(HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov. 14 ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a leading treatment in the fields of diabetes and obesity, with recent preclinical and clinical studies indicating significant ...

Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have ...

About The Study: In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated with a 2-fold higher risk of incident ...